Pembrolizumab for the treatment of gastric cancer

Suneel D. Kamath*, Aparna Kalyan, Al B Benson III

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.

Original languageEnglish (US)
Pages (from-to)1177-1187
Number of pages11
JournalExpert review of anticancer therapy
Volume18
Issue number12
DOIs
StatePublished - Dec 2 2018

Fingerprint

Stomach Neoplasms
Immunotherapy
Stomach
Dysbiosis
Therapeutics
Tumor Microenvironment
Combination Drug Therapy
Carcinogenesis
pembrolizumab
Neoplasms

Keywords

  • Gastric cancer
  • PD-1
  • PD-L1
  • immuno-oncology
  • immunotherapy
  • microsatellite instability
  • pembrolizumab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

@article{756bdd8f2d6a4191aa303359e62c16d7,
title = "Pembrolizumab for the treatment of gastric cancer",
abstract = "Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.",
keywords = "Gastric cancer, PD-1, PD-L1, immuno-oncology, immunotherapy, microsatellite instability, pembrolizumab",
author = "Kamath, {Suneel D.} and Aparna Kalyan and {Benson III}, {Al B}",
year = "2018",
month = "12",
day = "2",
doi = "10.1080/14737140.2018.1526084",
language = "English (US)",
volume = "18",
pages = "1177--1187",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "12",

}

Pembrolizumab for the treatment of gastric cancer. / Kamath, Suneel D.; Kalyan, Aparna; Benson III, Al B.

In: Expert review of anticancer therapy, Vol. 18, No. 12, 02.12.2018, p. 1177-1187.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pembrolizumab for the treatment of gastric cancer

AU - Kamath, Suneel D.

AU - Kalyan, Aparna

AU - Benson III, Al B

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.

AB - Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.

KW - Gastric cancer

KW - PD-1

KW - PD-L1

KW - immuno-oncology

KW - immunotherapy

KW - microsatellite instability

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85054390956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054390956&partnerID=8YFLogxK

U2 - 10.1080/14737140.2018.1526084

DO - 10.1080/14737140.2018.1526084

M3 - Article

VL - 18

SP - 1177

EP - 1187

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 12

ER -